РОЛЬ ПАРВОВИРУСА В19 В РАЗВИТИИ ВОСПАЛИТЕЛЬНОЙ КАРДИОМИОПАТИИ
https://doi.org/10.20996/1819-6446-2013-9-5-542-550
Аннотация
Обсуждается проблема воспалительной кардиомиопатии. Рассматриваются вопросы этиологии, патогенеза, диагностики и лечения воспалительной кардиомиопатии с особым вниманием на роль парвовируса В19.
Об авторах
А. Ю. Щедрина
Российский кардиологический научно-производственный комплекс, Москва
Россия
Аспирант отдела заболеваний миокарда и сердечной недостаточности
Россия
Аспирант отдела заболеваний миокарда и сердечной недостаточности
А. А. Скворцов
Российский кардиологический научно-производственный комплекс, Москва
Россия
Доктор медицинских наук, ведущий научный сотрудник отдела заболеваний миокарда и сердечной недостаточности
Россия
Доктор медицинских наук, ведущий научный сотрудник отдела заболеваний миокарда и сердечной недостаточности
К. А. Зыков
Российский кардиологический научно-производственный комплекс, Москва
Россия
Доктор медицинских наук, руководитель лаборатории иммунопатологии сердечно-сосудистых заболеваний
Россия
Доктор медицинских наук, руководитель лаборатории иммунопатологии сердечно-сосудистых заболеваний
А. А. Сафиуллина
Российский кардиологический научно-производственный комплекс, Москва
Россия
Аспирант отдела заболеваний миокарда и сердечной недостаточности
Россия
Аспирант отдела заболеваний миокарда и сердечной недостаточности
С. Н. Терещенко
Российский кардиологический научно-производственный комплекс, Москва
Россия
Доктор медицинских наук, профессор, руководитель того же отдела
Россия
Доктор медицинских наук, профессор, руководитель того же отдела
Список литературы
1. Mc Carthy RE, Boehmer JP, Hruban NH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342:690-5.
2. Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008;99: 95-114.
3. Maron BJ, Towbin JA, Thiene G. et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006; 113: 1807-1816.
4. D'Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001;85:499-504.
5. Sekiguchi M, Nunoda S, Hiroe M, et al. Prognosis of patients with acute viral myocarditis in whom endomyocardial biopsies and/or autopsies were performed: an ISFC survey. In: Sekiguki M, Richardson PJ, eds. Prognosis and reatment of cardiomyopathies and myocarditis. Tokyo: University of Tokyo Press; 1994:189-200.
6. Quigley PJ, Richardson PJ, Meany BT, et al. Long-term follow up of acute myocarditis. Correlation of ventricular function and outcome. Eur Heart J 1987; 8(1):39-42.
7. Piran S, Liu P, Morales A, Hershberger RE. Where Genome Meets Phenome: Rationale for Integrating Genetic and Protein Biomarkers in the Diagnosis and Management of Dilated Cardiomyopathy and Heart Failure. JACC 2012; 60(4): 283-289.
8. Röttgen R, Christiani R, Freyhardt P et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol 2011; 21(6): 1259-66.
9. Mahrholdt H, Goedecke C, Wagner A, et al. Multimedia article. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109:1250-8.
10. Cooper LT, Baughman KL, Feldman AM et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Journal of the American College of Cardiology 2007; 50 (19): 1914-31.
11. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989;14:915-20.
12. Noutsias M, Pauschinger M, Schultheiss HP, Kühl U. Advances in the immunohistological diagnosis of inflammatory cardiomyopathy. Eur Heart J 2002;4(1):154-162.
13. Kenneth L. Baughman Diagnosis of Myocarditis Death of Dallas Criteria. Circulation 2006;113;593-595.
14. Deckers JW, Hare JM, Baughman KM. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Card 1992; 19: 43-47.
15. Shirani J, Freant LJ, Roberts WC. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol 1993; 72: 952-957.
16. Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Ninth Edition. Philadelphia, Pa: Elsevier Saunders; 2012.
17. Kuhl U, Pauschinger M, Seeberg B. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965
18. Schultz JC, Hilliard AA, Cooper LT Jr, Rihal SC. Diagnosis and Treatment of Viral Myocarditis Mayo Clin Proc 2009;84(11):1001-1009.
19. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1 (7898): 72-73.
20. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
21. Brown KE, Young NS, Liu JM. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit Rev Oncol Hematol 1994; 16:1-31.
22. Osaki M, Matsubara K, Iwasaki T et al. Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease. Ann Hematol 1999 Feb;78(2):83-6.
23. Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000; 12:289-294.
24. Dingli D, Pfizenmaier DH, Arromdee E et al. Severe digital arterial occlusive disease and acute parvovirus B19 infection. Lancet 2000;356:312-314.
25. Drago F, Semino M, Rampini P, Rebora P. Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthem. Br J Dermatol 1999;141:160-161.
26. Barah F, Vallely PJ, Chiswick ML et al. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 2001;358:729-730.
27. Crane J. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can 2002;24:727-743.
28. Tschöpe C, Bock CT, Kasner M et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111(7); 879-86
29. Kuhl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111:887-893.
30. Klein RM, Jiang H, Niederacher D et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol 2004;93:300-309.
31. Bock CT, Klingel K, Kandolf R. Human В19 associated myocarditis. N Engl J Med 2010;362;13
32. Bowles NE, Ni J, Kearney DL. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2002;42:466
33. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 96 2005;96: 144.
34. Stewart GС, Lopez-Molina J, Gottumukkala RV et al. Myocardial Parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 2011;4(1): 71-8.
35. Kuethe F, Lindner J, Matschke M et al. Prevalence of Parvovirus B19 and Human Bocavirus DNA in the Heart of Patients with no Evidence of Dilated Cardiomyopathy or Myocarditis. Clinical Infectious Diseases 2009; 49:1660-6.
36. Brown KE, Hibbs JR, Gallinella G et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen) N Engl J Med 1994;330: 1192-1196
37. Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. New York: Springer Science; 2012.
38. Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cell. J Virol 2001;75: 4110-4116.
Рецензия
Для цитирования:
Щедрина А.Ю., Скворцов А.А., Зыков К.А., Сафиуллина А.А., Терещенко С.Н. РОЛЬ ПАРВОВИРУСА В19 В РАЗВИТИИ ВОСПАЛИТЕЛЬНОЙ КАРДИОМИОПАТИИ. Рациональная Фармакотерапия в Кардиологии. 2013;9(5):542-550. https://doi.org/10.20996/1819-6446-2013-9-5-542-550
For citation:
Shchedrina A.Yu., Skvortsov A.A., Zykov K.A., Safiullina A.A., Tereshchenko S.N. THE ROLE OF PARVOVIRUS B19 IN THE DEVELOPMENT OF INFLAMMATORY CARDIOMYOPATHY. Rational Pharmacotherapy in Cardiology. 2013;9(5):542-550. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-5-542-550
Просмотров:
841
Послать статью по эл. почте 